SELLAS Life Sciences shares soared on Tuesday after the company said its experimental leukemia vaccine helped patients live longer in a late-stage trial. The stock traded at $19.71 at 2:27 p.m. Eastern time, up $12.24, or 164%, from Monday’s close of $7.47.
The company said its Phase 3 REGAL trial of galinpepimut-S, or GPS, met its main goal of improving overall survival in patients with acute myeloid leukemia who had reached a second or later remission and could not have a stem cell transplant. Patients given the vaccine lived a median 24.0 months, compared with 14.7 months for those on the best available treatment, a 41% lower risk of death.
SELLAS said the vaccine was generally well tolerated, with no new safety signals. It plans to meet with the Food and Drug Administration to discuss a faster filing path and is preparing to submit an application for approval in the first half of 2027. Full results will be presented at a medical conference.
Chief Executive Angelos Stergiou called the results “a defining milestone for SELLAS.”
…
That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.




